Cargando…

The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease with considerable impact on patients and carers as the disease progresses. Currently few treatments are available. We aimed to evaluate the clinical and cost-effectiveness of available treatments for IPF. METHODS: System...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loveman, Emma, Copley, Vicky R, Colquitt, Jill L, Scott, David A, Clegg, Andy J, Jones, Jeremy, O’Reilly, Katherine MA, Singh, Sally, Bausewein, Claudia, Wells, Athol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247619/ https://www.ncbi.nlm.nih.gov/pubmed/25410822 http://dx.doi.org/10.1186/2050-6511-15-63

Ejemplares similares

Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
por: Loveman, Emma, et al.
Publicado: (2015)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
por: Scott, David A., et al.
Publicado: (2019)

Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis
por: Bajwah, Sabrina, et al.
Publicado: (2021)

The cost-effectiveness of osteochondral allograft transplantation in the knee
por: Mistry, Hema, et al.
Publicado: (2019)

Meniscal allograft transplantation after meniscectomy: clinical effectiveness and cost-effectiveness
por: Waugh, Norman, et al.
Publicado: (2019)

Allografts in reconstruction of the posterior cruciate ligament: a health economics perspective
por: Waugh, Norman, et al.
Publicado: (2019)

Autograft or allograft for reconstruction of anterior cruciate ligament: a health economics perspective
por: Mistry, Hema, et al.
Publicado: (2019)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Improving Uptake of Postnatal Checking of Blood Glucose in Women Who Had Gestational Diabetes Mellitus in Universal Healthcare Settings: A Systematic Review
por: Sanderson, Helen, et al.
Publicado: (2018)

Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada
por: Tarride, Jean-Eric, et al.
Publicado: (2018)

The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications
por: Wells, Athol U
Publicado: (2013)

Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2017)

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Mistry, Hema, et al.
Publicado: (2019)

The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study
por: Cox, Ingrid A., et al.
Publicado: (2022)

Communication difficulties reported by patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group study
por: Masefield, Sarah, et al.
Publicado: (2019)

Quantitative CT‐derived vessel metrics in idiopathic pulmonary fibrosis: A structure–function study
por: Jacob, Joseph, et al.
Publicado: (2019)

Economic consequences of idiopathic pulmonary fibrosis in Denmark
por: Hilberg, Ole, et al.
Publicado: (2018)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy
por: Perais, Jennifer, et al.
Publicado: (2023)

Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
por: Molyneaux, Philip L., et al.
Publicado: (2017)

Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy
por: Ravaglia, Claudia, et al.
Publicado: (2019)

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis
por: Samara, Katerina D., et al.
Publicado: (2017)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
por: Dempsey, Timothy M., et al.
Publicado: (2022)

Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis
por: Humphries, Stephen M., et al.
Publicado: (2022)

Serial Decline in Lung Volume Parameters on Computed Tomography (CT) Predicts Outcome in Idiopathic Pulmonary Fibrosis (IPF)
por: Robbie, Hasti, et al.
Publicado: (2022)

Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease-related lung fibrosis
por: Jaeger, Veronika K., et al.
Publicado: (2019)

A qualitative exploration of people living with idiopathic pulmonary fibrosis experience of a virtual pulmonary rehabilitation programme
por: O’Shea, Orlagh, et al.
Publicado: (2022)

Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis
por: Witt, Sabine, et al.
Publicado: (2019)

Keeping time on liver fibrosis
por: O’Reilly, Steven
Publicado: (2021)

Clinical Relevance of Plasma Prostaglandin F(2α) Metabolite Concentrations in Patients with Idiopathic Pulmonary Fibrosis
por: Aihara, Kensaku, et al.
Publicado: (2013)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
por: Clay, Emilie, et al.
Publicado: (2019)

MicroRNAs in fibrosis: opportunities and challenges
por: O’Reilly, Steven
Publicado: (2016)

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
por: George, Peter M, et al.
Publicado: (2020)

Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response
por: Cottin, Vincent, et al.
Publicado: (2011)

Effect of Nintedanib in Patients with Progressive Pulmonary Fibrosis in Subgroups with Differing Baseline Characteristics
por: Kolb, Martin, et al.
Publicado: (2023)

Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study
por: Nolan, Claire M, et al.
Publicado: (2021)

Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study
por: Raimundo, Karina, et al.
Publicado: (2016)

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?
por: Cottin, Vincent, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u2opjlgi83eb2v6kbqucshilsn